Dr. Nabeel Y. Hamzeh, MD

Dr. Hamzeh practices at University of Iowa Health Care Medical Center in Iowa City, Iowa, part of The University of Iowa.

Dr. Hamzeh's NPI, 1437193745, was assigned on June 16, 2006. Dr. Hamzeh holds Iowa license MD-44539.

Dr. Hamzeh's primary practice is University of Iowa Health Care Medical Center, at 200 Hawkins Drive, Iowa City, IA 52242 in Johnson County. The practice phone is (319) 356-1616.

Dr. Hamzeh's primary practice is University of Iowa Health Care Medical Center in Iowa City, Iowa, part of The University of Iowa. Dr. Hamzeh is also affiliated with Southeast Iowa Regional Medical Center, West Burlington. The medical group on file is Scanlan Center for School Mental Health Clinic.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hamzeh practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Hamzeh's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dmand AI has Dr. Hamzeh's licenses on file in 2 states: Iowa and Colorado.

CMS data shows 412 Medicare services from Dr. Hamzeh across 8 procedure codes in 2024, for 265 Medicare patients. Medicare paid $32,118 for them.

CMS counts 265 Medicare patients who saw Dr. Hamzeh in 2024. The largest group is 65 to 74, with 119 patients. 74% of them have high blood pressure, and 71% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hamzeh's median patient age at 71, with 54% women.

In 2024, Dr. Hamzeh wrote 833 Medicare Part D claims for 116 patients. 68% of them were for generic drugs. CMS names the drug for 678 of them, across 18 drugs with 11 or more claims each, at $1,580,638 in total drug cost. In 2023, CMS named 619 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Hamzeh for performance year 2024, reported as part of a group. Dr. Hamzeh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hamzeh as offering telehealth.

Dmand AI links 38 papers to Dr. Hamzeh, published from 2011 to 2024. 2022 was the busiest year, with 5. The most frequent topics are Sarcoidosis, Sarcoidosis, Pulmonary and Berylliosis. Dr. Hamzeh has published most often in PLoS One. Dr. Hamzeh's most frequent co-authors are Lisa M. Maier, MD, Robert P. Baughman, MD and Daniel A. Culver, DO.

Dmand AI links Dr. Hamzeh to 3 clinical trials. Conditions studied include Idiopathic Pulmonary Fibrosis, Sarcoidosis and Sarcoidosis, Pulmonary.

CMS Open Payments shows 6 general payments to Dr. Hamzeh from 1 drug or device company from 2022 to 2023. Consulting fees make up the largest share, 88% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $9,337.